Northwestern's McCormick School of Engineering

Post-Stroke Injection Protects the Brain in Preclinical Study

A nanomaterial based on a platform developed by Professor Samuel Stupp crosses the blood-brain barrier and targets harmful ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
FiercePharma

Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
Times Argus

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the effector enzyme of the lectin pathway, blocking pathway activation while preserving ...